Efficacy and Safety of Pitavastatin in Patients with Impaired Glucose Tolerance: An Updated Review

Rao, 2004, Impaired glucose tolerance and impaired fasting glucose, Am Fam Physician, 69, 1961 Maji, 2005, Prevention of type 2 diabetes in the prediabetic population, J Indian Med Assoc, 103, 609 Hoy, 2017, Pitavastatin: A review in hypercholesterolemia, Am J Cardiovasc Drugs, 17, 157, 10.1007/s40256-017-0213-8 Duggan, 2012, Pitavastatin: A review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia, Drugs, 72, 565, 10.2165/11207180-000000000-00000 Eyth, 2023, Glucose Tolerance Test Sulaiman, 2010, Is using WHO criteria for impaired fasting glycaemia appropriate as an indication for OGTT in patients at high risk of developing diabetes?, Int J Clin Pract, 64, 1793, 10.1111/j.1742-1241.2010.02383.x Choi, 2002, Comparison of ADA and WHO criteria for the diagnosis of diabetes in elderly Koreans, Diabet Med, 19, 853, 10.1046/j.1464-5491.2002.00783.x Amoah, 2002, Undiagnosed diabetes and impaired glucose regulation in adult Ghanaians using the ADA and WHO diagnostic criteria, Acta Diabetol, 39, 7, 10.1007/s005920200006 Harris, 1989, Impaired glucose tolerance in the U.S. population, Diabetes Care, 12, 464, 10.2337/diacare.12.7.464 O'Rahilly, 1994, Insulin resistance as the major cause of impaired glucose tolerance: A self-fulfilling prophesy?, Lancet, 344, 585, 10.1016/S0140-6736(94)91969-0 Yudkin, 1994, Insulin resistance and impaired glucose tolerance, Lancet, 344, 1294 Alcolado, 1994, Insulin resistance and impaired glucose tolerance, Lancet, 344, 1293, 10.1016/S0140-6736(94)90778-1 Joffe, 1994, Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus, Lancet, 344, 1705, 10.1016/S0140-6736(94)90488-X Tudurí, 2022, The pancreatic β-cell in ageing: Implications in age-related diabetes, Ageing Res Rev, 80, 10.1016/j.arr.2022.101674 Freeman, 2022, Insulin resistance Reaven, 2005, Insulin resistance, the insulin resistance syndrome, and cardiovascular disease, Panminerva Med, 47, 201 Kerper, 2022, Pancreatic β-Cell development and regeneration, Cold Spring Harb Perspect Biol, 14, 10.1101/cshperspect.a040741 Cerf, 2013, Beta cell dysfunction and insulin resistance, Front Endocrinol (Lausanne), 4, 37, 10.3389/fendo.2013.00037 Rooney, 2023, Global prevalence of prediabetes, Diabetes Care, 46, 1388, 10.2337/dc22-2376 Benjamin, 2003, Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention, Diabetes Care, 26, 645, 10.2337/diacare.26.3.645 Bergman, 2013, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus, Endocrine, 43, 504, 10.1007/s12020-012-9830-9 Alberti, 1998, Impaired glucose tolerance: what are the clinical implications?, Diabetes Res Clin Pract, 40 Vermeer, 2006, Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke, Stroke, 37, 1413, 10.1161/01.STR.0000221766.73692.0b Laakso, 2017, Diabetes secondary to treatment with statins, Curr Diab Rep, 17, 10, 10.1007/s11892-017-0837-8 Galicia-Garcia, 2020, Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights, Int J Mol Sci, 21, 4725, 10.3390/ijms21134725 Grunwald, 2022, Statins aggravate the risk of insulin resistance in human muscle, Int J Mol Sci, 23, 2398, 10.3390/ijms23042398 Goyal, 2014, Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study, Can J Diabetes, 38, 466, 10.1016/j.jcjd.2014.01.006 Kulkarni, 2004, The islet beta-cell, Int J Biochem Cell Biol, 36, 365, 10.1016/j.biocel.2003.08.010 Qian, 2010, Statins and beta-cell function, Med Sci Monit, 16, HY1 Saini, 2011, Coenzyme Q10: The essential nutrient, J Pharm Bioallied Sci, 3, 466, 10.4103/0975-7406.84471 Nawarskas, 2005, HMG-CoA reductase inhibitors and coenzyme Q10, Cardiol Rev, 13, 76, 10.1097/01.crd.0000154790.42283.a1 Robinson, 2015, Statins and diabetes risk: How real is it and what are the mechanisms?, Curr Opin Lipidol, 26, 228, 10.1097/MOL.0000000000000172 Licito, 2020, Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: Preliminary results, Eur Rev Med Pharmacol Sci, 24, 469 Saito, 2011, Pitavastatin: An overview, Atheroscler Suppl, 12, 271, 10.1016/S1567-5688(11)70886-8 Chapman, 2011, Pitavastatin: Novel effects on lipid parameters, Atheroscler Suppl, 12, 277, 10.1016/S1567-5688(11)70887-X Miyamoto-Sasaki, 2013, Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients, J Atheroscler Thromb, 20, 708, 10.5551/jat.17210 Qadir, 2014, Pitavastatin is a potent anti-inflammatory agent in the rat paw model of acute inflammation, Pak J Pharm Sci, 27, 2169 Davignon, 2004, Role of endothelial dysfunction in atherosclerosis, Circulation, 109, III27 Wang, 2005, Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells, Life Sci, 76, 2257, 10.1016/j.lfs.2004.12.003 Dubois-Deruy, 2020, Oxidative stress in cardiovascular diseases, Antioxidants (Basel), 9, 864, 10.3390/antiox9090864 Ansari, 2012, Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats, Toxicol Mech Methods, 22, 67, 10.3109/15376516.2011.603391 Bhatti, 2022, Pitavastatin LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Pitavastatin. [Updated 2021 Dec 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548065/. Accessed July 16, 2023. García, 2003, Clinical pharmacokinetics of statins, Methods Find Exp Clin Pharmacol, 25, 457, 10.1358/mf.2003.25.6.769652 Fujino, 2002, Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase–effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice, Drug Metab Pharmacokinet, 17, 449, 10.2133/dmpk.17.449 Adams, 2020, Pitavastatin for lowering lipids, Cochrane Database Syst Rev, 6 Teramoto, 2012, The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C, Expert Opin Pharmacother, 13, 859, 10.1517/14656566.2012.660525 Pirillo, 2017, Pitavastatin and HDL: Effects on plasma levels and function(s), Atheroscler Suppl, 27, e1, 10.1016/j.atherosclerosissup.2017.05.001 Kosmas, 2018, High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease, Drugs Context, 7, 10.7573/dic.212525 Gotto, 2010, Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia, Expert Rev Cardiovasc Ther, 8, 1079, 10.1586/erc.10.82 Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol, 81, 7B, 10.1016/S0002-9149(98)00031-9 Sadeq, 2023, A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin, Curr Rev Clin Exp Pharmacol, 18, 120, 10.2174/2772432817666220531115314 Saiki, 2021, CAVI-lowering effect of pitavastatin may be involved in the prevention of cardiovascular disease: subgroup analysis of the TOHO-LIP, J Atheroscler Thromb, 28, 1083, 10.5551/jat.60343 Zhao, 2015, Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia, J Zhejiang Univ Sci B, 16, 380, 10.1631/jzus.B1400181 Vallejo-Vaz, 2015, Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes, Atherosclerosis, 241, 409, 10.1016/j.atherosclerosis.2015.06.001 Zhang, 2018, Cardiovasc Drugs Ther, 32, 581, 10.1007/s10557-018-6826-6 Eyth, 2023, Hemoglobin A1C Teramoto, 2011, Pitavastatin: Clinical effects from the LIVES Study, Atheroscler Suppl, 12, 285, 10.1016/S1567-5688(11)70888-1 Braun, 2018, Effects of pitavastatin on insulin sensitivity and liver fat: A randomized clinical trial, J Clin Endocrinol Metab, 103, 4176, 10.1210/jc.2018-01446 Beyaz, 2017, Pitavastatin ve diyabet gelişimi [Pitavastatin and new diabetes development], Turk Kardiyol Dern Ars, 45, 13 Taguchi, 2018, High-Dose Versus low-dose pitavastatin in Japanese patients with stable Coronary Artery Disease (REAL-CAD): A randomized superiority trial, Circulation, 137, 1997, 10.1161/CIRCULATIONAHA.117.032615 Lee, 2020, Safety and efficacy of pitavastatin in patients with impaired fasting glucose and hyperlipidemia: A randomized, open-labeled, multicentered, phase IV study, Clin Ther, 42, 2036, 10.1016/j.clinthera.2020.07.013 Hong, 2017, Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II, Korean J Intern Med, 32, 656, 10.3904/kjim.2016.016 Poolsup, 2012, Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia, J Clin Pharm Ther, 37, 166, 10.1111/j.1365-2710.2011.01274.x